Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.
- Second consecutive quarter of positive operating cash flow at $359k
- Record $560k single wholesale order boosts Australian sales
- Auracast™ platform expands with Clinico Inc. and international distributors
- AI audio licensing deal with Optek Microelectronics progressing
- Cash balance improved to $1.05 million at quarter end
Positive Cash Flow Momentum Continues
Audeara Limited (ASX:AUA) has delivered a second consecutive quarter of positive net operating cash flow, reporting $359,000 for Q3 FY26 and $380,000 year-to-date. This marks a significant turnaround from a $928,000 operating cash outflow in the prior corresponding period. The company’s cash balance increased to $1.05 million by 31 March 2026, up from $734,000 at the end of December 2025, reflecting improved cash management and stronger customer receipts.
CEO Dr James Fielding highlighted the company’s dual revenue engines: a wholesale channel generating near-term cash and a technology platform designed for global licensing scale. While both streams introduce timing variability, they are delivering increasing demand and momentum. This operational shift sets the stage for an inflection point where technology licensing revenue grows beyond engineering costs, supported by a robust wholesale base.
Australian Wholesale Sales Hit New Highs
The Australian wholesale channel remains the backbone of Audeara’s commercial operations. The quarter included a record single purchase order worth $560,000 from a major wholesale customer, the largest in the company’s history. This order was recognised as revenue and cash receipts within the quarter. Year-to-date Australian wholesale sales have reached $2.24 million, already 25% higher than the full FY25 total, driven by the rollout of the new Auracast™ portfolio into key national accounts.
This strong wholesale performance follows the company’s earlier report of a record $560,000 purchase order, underscoring sustained growth in this segment. The wholesale channel’s success provides a reliable cash flow foundation while the company scales its technology licensing efforts.
Auracast™ Platform and Technology Licensing Expand Globally
Audeara’s Auracast™ broadcast technology platform continues to gain traction internationally. The company expanded its partnership with Clinico Inc., progressing multiple white-label product programs and securing initial purchase orders to commence production. This builds on prior announcements of Auracast™ programs with Clinico, reflecting a strategic push to scale the technology via partner-led channels.
Additionally, Auracast™ device sales now include distributors in Japan, the USA, and Australia, with negotiations underway for European and broader Asian market expansion. Audeara’s participation in the Trade and Investment Queensland health innovation mission to SusHi Tech Tokyo 2026 later this month will showcase its technology to thousands of industry leaders and investors, potentially accelerating partnerships in the Asia-Pacific region.
On the AI front, Audeara’s chip-level audio algorithms are being embedded into Optek Microelectronics’ system-on-chip platforms, enabling a royalty-style revenue stream on a fee-per-chip basis across global OEM and ODM programs. Initial demonstrations are planned for late April, marking a key step in scaling the company’s licensing business. This follows the earlier reported AI chip-level licensing deal with OPTEK Microelectronics and demonstrates progress toward commercialising its AI audio technology globally.
China Market Strategy Under Revision
After securing NMPA certification and completing initial market testing in China, Audeara’s partner is now refining its go-to-market strategy to optimise launch and scale commercialisation through China’s primary e-commerce and online healthcare platforms. While commercial traction remains in a build-up phase, the company remains confident in the long-term growth opportunity, leveraging its capital-light licensing model. The market insights gained are expected to inform a more effective commercial push in upcoming quarters.
Product Development with ShokzHear Advances
Audeara continues to develop its open-ear listening product with ShokzHear, focusing on optimising performance and aligning with partner go-to-market strategies. The program is progressing toward commercial rollout milestones, aiming to expand Audeara’s footprint in the health-focused listening device segment through a scalable, partner-led revenue channel.
Bottom Line?
Audeara’s sustained positive cash flow and expanding technology partnerships position it for scaling growth, but timing variability in licensing revenues and evolving China market strategy warrant close monitoring.
Questions in the middle?
- How quickly will Auracast™ technology licensing translate into predictable recurring revenues?
- What impact will the refined China market strategy have on commercial sales momentum?
- Can the Australian wholesale channel maintain its recent growth trajectory amid broader market competition?